Clinical Trials Browser

Cytokine Release Syndrome, Multiple Myeloma

NCT06806033 2026-03-31

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

100 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07502118 2026-03-30

NexCAR19

Phase 2/3 Recruiting

40 enrolled

Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06377059 2026-03-13

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Phase NA Recruiting

100 enrolled

Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT06421675 2025-11-14

EMBRACE

Phase 2 Recruiting

40 enrolled

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

20 enrolled

Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Phase 1 Recruiting

20 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

Clinical Trials

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NexCAR19

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

EMBRACE

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab